Literature DB >> 6800190

Serum ferritin levels in thalassemias and the effect of splenectomy.

P Pootrakul, V Vongsmasa, P La-ongpanich, P Wasi.   

Abstract

Iron overload is a constant and the more important complication in thalassemia. Serum ferritin concentration accurately reflects body iron stores. A total of 245 thalassemic patients aged 12-55 years were examined, 71 having Hb H disease and 174 beta-thalassemia/Hb E disease. The patients received minimal or no blood transfusions. 73 patients with beta-thalassemia/Hb E were studied 1-28 years after splenectomy. The serum ferritin levels in both Hb H and beta-thalassemia/Hb E patients were higher than normal. They were higher in beta-thalassemia/Hb E than Hb H disease. Most striking was the significantly higher serum ferritin levels in splenectomized patients with beta-thalassemia/Hb E disease than in the nonsplenectomized ones. The observation is compatible with previous observations that splenectomy in thalassemia is associated with increased iron deposition and increased transferrin iron saturation. The further increase in iron overload after splenectomy in thalassemia should be borne in considering removal of this organ.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800190     DOI: 10.1159/000207129

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

1.  Serum ferritin in thalassemia intermedia.

Authors:  Ravi Shah; Amita Trehan; Reena Das; R K Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-06       Impact factor: 0.900

Review 2.  The hemoglobin E thalassemias.

Authors:  Suthat Fucharoen; David J Weatherall
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

3.  Organ-specific crystalline structures of ferritin cores in beta-thalassemia/hemoglobin E.

Authors:  T G St Pierre; K C Tran; J Webb; D J Macey; B R Heywood; N H Sparks; V J Wade; S Mann; P Pootrakul
Journal:  Biol Met       Date:  1991

4.  Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation.

Authors:  Anyapat Atipimonpat; Panjaree Siwaponanan; Archrob Khuhapinant; Saovaros Svasti; Kasama Sukapirom; Ladawan Khowawisetsut; Kovit Pattanapanyasat
Journal:  Ann Hematol       Date:  2021-06-21       Impact factor: 3.673

Review 5.  Haemoglobinopathies in southeast Asia.

Authors:  Suthat Fucharoen; Pranee Winichagoon
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

Review 6.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

7.  Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.

Authors:  Ali T Taher; John B Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Yiyun Zhang; M Domenica Cappellini
Journal:  Am J Hematol       Date:  2013-05-13       Impact factor: 10.047

8.  Glutathione redox system in β -thalassemia/Hb E patients.

Authors:  Ruchaneekorn W Kalpravidh; Thongchai Tangjaidee; Suneerat Hatairaktham; Ratiya Charoensakdi; Narumol Panichkul; Noppadol Siritanaratkul; Suthat Fucharoen
Journal:  ScientificWorldJournal       Date:  2013-10-07

Review 9.  When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.

Authors:  A T Taher; A Radwan; V Viprakasit
Journal:  Vox Sang       Date:  2014-10-07       Impact factor: 2.144

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.